This indicates that screening using f-Hb has lower sensitivity for CRC in women than in men and it might be expected that the effect of screening on CRC mortality would be less in women than in men; indeed, the results of long-term follow-up of the Minnesota trial of gFOBT screening support this conclusion.10 The gene discussed is GSTM1; the disease is colorectal carcinoma.